false
OasisLMS
Login
Catalog
Kidney Week 2026 Early Program On-Demand - Advance ...
In Vitro and In Vivo Models to Assess siRNA Target ...
In Vitro and In Vivo Models to Assess siRNA Targeting and Efficacy
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Alphika Sehgal of JudoBio presented a megalin-targeted siRNA platform designed to deliver genetic medicines to kidney proximal tubule cells. Because conventional delivery approaches face kidney filtration barriers, the company attaches proprietary ligands and linkers to siRNAs, enabling receptor-mediated uptake after subcutaneous injection.<br /><br />Across extensive mouse studies, the team optimized more than 250 ligand, linker, and siRNA combinations. In vitro proximal-tubule models and in vivo experiments indicated megalin-dependent uptake; increasing ligand valency improved kidney exposure and gene knockdown. The conjugates showed kidney-selective distribution, durable effects lasting weeks to months after a single dose, and activity across multiple targets. Similar kidney and proximal-tubule delivery was observed in monkeys, alongside changes in urinary solute levels after targeting a transporter.<br /><br />The platform is modular and may support combined targeting of multiple genes. Sehgal reported encouraging preclinical safety and efficacy findings and said the company is preparing for clinical translation. In discussion, she noted that uptake does not always translate directly into activity, and that ligand affinity and endosomal escape require further optimization.
Asset Caption
Alfica Sehgal, PhD
Meta Tag
Speaker
Alfica Sehgal
Keywords
megalin-targeted siRNA
kidney proximal tubule
genetic medicines
receptor-mediated uptake
subcutaneous injection
ligand valency
preclinical safety
Alfica Sehgal
×
Please select your language
1
English